Clinical pharmacokinetics of dorzolamide
Clinical Pharmacokinetics, ISSN: 0312-5963, Vol: 41, Issue: 3, Page: 197-205
2002
- 42Citations
- 39Captures
- 3Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations42
- Citation Indexes42
- 42
- CrossRef14
- Captures39
- Readers39
- 39
- Mentions3
- News Mentions2
- News2
- References1
- Wikipedia1
Most Recent News
Development and Validation of Stability Indicting HPLC Method for the Separation and Simultaneous Analysis of Timolol, Dorzolamide and Latanoprost Inophthalmic formulations
A. Krishnamanjari Pawar1*, Chandana Mannepalli2 1Associate Professor, A. U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India. 2Research Scholar, A. U. College of Pharmaceutical Sciences,
Review Description
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and therefore to the desired therapeutic effect. In the systemic circulation, dorzolamide is bound mainly to carbonic anhydrase in red blood cells. It is slowly metabolised to N-de-ethyldorzolamide, which in turn is also stored in red blood cells. The very slow elimination (half-life >4 months) of both substances takes place via the renal route. However, the inhibition of carbonic anhydrase in red blood cells is moderate in the course of a topical treatment, avoiding systemic adverse effects. This review summarises the pharmacokinetic and pharmacodynamic properties of dorzolamide and its metabolite in eye tissues and in the systemic circulation.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036230547&origin=inward; http://dx.doi.org/10.2165/00003088-200241030-00004; http://www.ncbi.nlm.nih.gov/pubmed/11929320; http://link.springer.com/10.2165/00003088-200241030-00004; https://dx.doi.org/10.2165/00003088-200241030-00004; https://link.springer.com/article/10.2165/00003088-200241030-00004
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know